<DOC>
	<DOCNO>NCT02683850</DOCNO>
	<brief_summary>This prospective , non-randomized , open-label study ass take Omega-3 SPM™ soft gel supplement four week increase quality life adult chronic pain .</brief_summary>
	<brief_title>Influence Omega-3 SPM Supplement Quality Life</brief_title>
	<detailed_description>One third America population affect chronic pain . The societal cost associate chronic pain $ 635 billion dollar annually . Prescribed pain medication may negative side effect , cause addiction . Having alternative treatment reduce inflammation side effect associate chronic pain may improve quality life million . This prospective , non-randomized , open-label study ass take Omega-3 SPM™ soft gel supplement four week increase quality life adult chronic pain . SPM™ softgels dietary supplement intend reduce pain inflammation . Up 40 men woman chronic pain recruit . Outcome measure collect baseline , 2 week , 4 week primary endpoint 4 week . The primary outcome pilot study include questionnaire assess quality life . Exploratory outcomes assess safety tolerability , change anxiety depression well level pain , blood marker associate inflammation .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>Age 2070 Body mass index 19 kg/m2 40 kg/m2 Have chronic pain last 3 month longer Have moderate severe pain define average level pain score great equal 4 PROMIS43 Profile Pain Intensity subscale Willing blood drawn three time Maintained stable medication , dietary supplement therapy pain least 30 day willing continue therapy add new therapy duration study unless medically advise Able follow study protocol attend visit clinical practice associate Clinical Investigator Able speak , read understand English Initiation change use fish oil supplement , krill oil supplement , omega 3 supplement , omega 3based drug ( Lovaza® , etc . ) within past 3 month Initiation new pain medication nonsteroidal antiinflammatory drug NSAIDS within past month [ aspirin , ibuprofen ( Advil® , Motrin® , Nuprin® ) , acetaminophen ( Tylenol® ) , naproxen ( Aleve® , Naprosyn® ) , codeine ( Vicodin® ) , morphine ( Dilaudid® ) , oxycodone ( OxyContin® , Percocet® ) fentanyl ( Duragesic® ) COX2 inhibitor , Celebrex® ) Currently take : Medication reduce tendency form blood clot [ warfarin , jantoven ( Coumadin® ) ; dabigatran ( Pradaxa® ) ; rivaroxaban , ( Xarelto® ) ; apixaban ( Eliquis® ) ] Statin use cholesterol reduction [ atorvastatin ( Lipitor® ) , fluvastatin ( Lescol® ) , lovastatin ( Mevacor® , Altocor® ) , pitavastatin ( Livalo® ) , pravastatin ( Pravachol® ) , rosuvastatin ( Crestor® ) simvastatin ( Zocor® ) ] ( include Red Yeast Rice also supplement CoQ10 ) Corticosteroids [ prednisone , dexamethasone , prednisolone ( Orapred® , Prelone® , Pediapred® ) , methylprednisolone ( Medrol® ) ] ( include topical corticosteroid dermatological condition nasally inhale asthma , rhinitis sinusitis ) Daily aspirin &gt; 325 mg per day ( include low dose aspirin therapy 81 mg 325 mg per day ) Other medication supplement evaluate investigator casebycase basis Steroid injection , Prolotherapy , injection ligament , tendon , joint muscle past month initiation continuation therapy injection course study . Present past history following : Inflammatory disease ( e.g . rheumatoid arthritis , autoimmune disease , Crohn 's disease , diverticulitis , viral hepatitis , ulcerative colitis , systemic lupus , Parkinson 's disease , Alzheimer 's , ankylose spondylitis ) Blood clot disorder ( e.g. , phlebitis ) Diabetes ( selfreport ; include Type I Type II Diabetes include history Gestational Diabetes pregnancy ) Cancer within last 5 year ( exception basal cell carcinoma , squamous cell carcinoma , and/or carcinoma situ cervix ) Cardiovascular disease within last year , include limited : myocardial infarction , stroke , congestive heart failure ( CHF ) Kidney failure liver failure Current active pelvic inflammatory disease , urinary tract infection kidney infection Women lactating , pregnant planning pregnancy within next six month Difficulty aversion swallow soft gel , capsule , tablet pills Known intolerance allergy fish oil Upon administer NCNM Adverse Event Monitoring form screening , sign symptom Grade 3 ( severe medically significant immediately lifethreatening ) high report Currently participate another research study participate another study within last month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>